Literature DB >> 27757834

Transcriptome Profile Changes in Mice with MPTP-Induced Early Stages of Parkinson's Disease.

Anelya Kh Alieva1, Elena V Filatova2, Anna A Kolacheva3, Margarita M Rudenok2, Petr A Slominsky2, Mikhail V Ugrumov3, Maria I Shadrina2.   

Abstract

Parkinson's disease (PD) is one of the most common neurodegenerative diseases. Despite progress in the study of the molecular, genetic, and pathogenic mechanisms of PD, it is unclear which processes trigger the development of the pathology associated with PD. Models of the presymptomatic and early symptomatic stages of PD induced by MPTP have been used to analyze changes in transcriptome profile in brain tissues, to identify specific patterns and mechanisms underlying neurodegeneration in PD. The whole-transcriptome analysis in the brain tissues of the mice with MPTP-induced PD showed that striatum is involved in the pathogenesis in the earliest stages and the processes associated with vesicular transport may be altered. The expression profiles of the genes studied in the substantia nigra and peripheral blood confirm that lymphocytes from peripheral blood may reflect processes occurring in the brain. These data suggest that messenger RNA (mRNA) levels in peripheral blood may provide potential biomarkers of the neurodegeneration occurring in PD. The changes in expression at the mRNA and protein levels suggest that Snca may be involved in neurodegeneration and Drd2 may participate in the development of the compensatory mechanisms in the early stages of PD pathogenesis. Our data suggest that the brain cortex may be involved in the pathological processes in the early stages of PD, including the presymptomatic stage.

Entities:  

Keywords:  DRD2; Gene expression; MPTP; MPTP model; Parkinson’s disease; SNCA; Whole-transcriptome analysis

Mesh:

Year:  2016        PMID: 27757834     DOI: 10.1007/s12035-016-0190-y

Source DB:  PubMed          Journal:  Mol Neurobiol        ISSN: 0893-7648            Impact factor:   5.590


  50 in total

1.  Increased expression of dopamine receptors on lymphocytes in Parkinson's disease.

Authors:  P Barbanti; G Fabbrini; A Ricci; R Cerbo; E Bronzetti; B Caronti; C Calderaro; L Felici; F Stocchi; G Meco; F Amenta; G L Lenzi
Journal:  Mov Disord       Date:  1999-09       Impact factor: 10.338

2.  Incidence of Parkinson disease in Wakayama, Japan.

Authors:  Seiji Morioka; Kiyomi Sakata; Sohei Yoshida; Ekini Nakai; Mitsuru Shiba; Noriko Yoshimura; Tsutomu Hashimoto
Journal:  J Epidemiol       Date:  2002-11       Impact factor: 3.211

Review 3.  Animal models of Parkinson's disease: an empirical comparison with the phenomenology of the disease in man.

Authors:  M Gerlach; P Riederer
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

4.  Sequence variants in SLC6A3, DRD2, and BDNF genes and time to levodopa-induced dyskinesias in Parkinson's disease.

Authors:  Natalie Kaplan; Aya Vituri; Amos D Korczyn; Oren S Cohen; Rivka Inzelberg; Gilad Yahalom; Evgenia Kozlova; Roni Milgrom; Yael Laitman; Eitan Friedman; Saharon Rosset; Sharon Hassin-Baer
Journal:  J Mol Neurosci       Date:  2014-03-15       Impact factor: 3.444

5.  Parkinson's disease pharmacogenomics: new findings and perspectives.

Authors:  Artur F Schumacher-Schuh; Carlos R M Rieder; Mara H Hutz
Journal:  Pharmacogenomics       Date:  2014-06       Impact factor: 2.533

Review 6.  Targeting glutamatergic synapses in Parkinson's disease.

Authors:  Fabrizio Gardoni; Monica Di Luca
Journal:  Curr Opin Pharmacol       Date:  2014-11-17       Impact factor: 5.547

7.  Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study.

Authors:  C G Goetz; P F Burke; S Leurgans; E Berry-Kravis; L M Blasucci; R Raman; L Zhou
Journal:  Arch Neurol       Date:  2001-02

8.  Two molecular pathways initiate mitochondria-dependent dopaminergic neurodegeneration in experimental Parkinson's disease.

Authors:  Celine Perier; Jordi Bové; Du-Chu Wu; Benjamin Dehay; Dong-Kug Choi; Vernice Jackson-Lewis; Silvia Rathke-Hartlieb; Philippe Bouillet; Andreas Strasser; Jörg B Schulz; Serge Przedborski; Miquel Vila
Journal:  Proc Natl Acad Sci U S A       Date:  2007-05-02       Impact factor: 11.205

9.  Central and peripheral dopamine transporter reduction in Parkinson's disease.

Authors:  Francesca R Buttarelli; Gabriela Capriotti; Clelia Pellicano; Daniela Prosperi; Annapia Circella; Anna Festa; Morena Giovannelli; Anna Tofani; Francesco E Pontieri; Francesco Scopinaro
Journal:  Neurol Res       Date:  2008-12-05       Impact factor: 2.448

10.  Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists.

Authors:  Da Wei Huang; Brad T Sherman; Richard A Lempicki
Journal:  Nucleic Acids Res       Date:  2008-11-25       Impact factor: 16.971

View more
  7 in total

1.  MPTP Mouse Model of Preclinical and Clinical Parkinson's Disease as an Instrument for Translational Medicine.

Authors:  Eduard R Mingazov; Gulnara R Khakimova; Elena A Kozina; Alexei E Medvedev; Olga A Buneeva; Ara S Bazyan; Michael V Ugrumov
Journal:  Mol Neurobiol       Date:  2017-04-29       Impact factor: 5.590

2.  Expression Analysis of Genes Involved in Transport Processes in Mice with MPTP-Induced Model of Parkinson's Disease.

Authors:  Margarita M Rudenok; Maria I Shadrina; Elena V Filatova; Ivan N Rybolovlev; Maxim S Nesterov; Denis A Abaimov; Ruslan A Ageldinov; Anna A Kolacheva; Michael V Ugrumov; Petr A Slominsky; Anelya Kh Alieva
Journal:  Life (Basel)       Date:  2022-05-19

3.  Whole-Transcriptome Analysis of Mouse Models with MPTP-Induced Early Stages of Parkinson's Disease Reveals Stage-Specific Response of Transcriptome and a Possible Role of Myelin-Linked Genes in Neurodegeneration.

Authors:  A Kh Alieva; V S Zyrin; M M Rudenok; A A Kolacheva; M V Shulskaya; M V Ugryumov; P A Slominsky; M I Shadrina
Journal:  Mol Neurobiol       Date:  2018-02-03       Impact factor: 5.590

4.  Reduction of HIP2 expression causes motor function impairment and increased vulnerability to dopaminergic degeneration in Parkinson's disease models.

Authors:  Jinlin Su; Pei Huang; Meiling Qin; Qingqing Lu; Xiao Sang; Yijun Cai; Ying Wang; Fubing Liu; Rong Wu; Xiaoping Wang; Xiaoxing Jiang; Jian Wang; Qiang Sun; Shengdi Chen; Jin Xu
Journal:  Cell Death Dis       Date:  2018-10-03       Impact factor: 8.469

5.  VCP expression decrease as a biomarker of preclinical and early clinical stages of Parkinson's disease.

Authors:  Anelya Alieva; Margarita Rudenok; Elena Filatova; Alexey Karabanov; Olga Doronina; Kseniya Doronina; Anna Kolacheva; Mikhail Ugrumov; Sergey Illarioshkin; Petr Slominsky; Maria Shadrina
Journal:  Sci Rep       Date:  2020-01-21       Impact factor: 4.379

Review 6.  Development of early diagnosis of Parkinson's disease: Illusion or reality?

Authors:  Michael Ugrumov
Journal:  CNS Neurosci Ther       Date:  2020-06-29       Impact factor: 7.035

7.  Molecular Regulatory Mechanism and Toxicology of Neurodegenerative Processes in MPTP/Probenecid-Induced Progressive Parkinson's Disease Mice Model Revealed by Transcriptome.

Authors:  Weiwei Yang; Wenwen Hao; Zhuo Meng; Shiyan Ding; Xiaodi Li; Tao Zhang; Weixiao Huang; Lian Xu; Yu Zhang; Jian Yang; Xiaosong Gu
Journal:  Mol Neurobiol       Date:  2020-09-30       Impact factor: 5.590

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.